The Fleming Initiative is a partnership between Imperial College London 
and Imperial College Healthcare NHS Trust.
​
​
​​Our mission is ambitious and can only be achieved in partnership with others.
We work with a range of partners to tackle the global threat of antimicrobial resistance.
Working together to fight AMR
The Fleming Initiative are proud to have the support of a wide range of commercial and philanthropic partners.
Through this support the Initiative has secured its first £100m to:
-
kickstart global programmes of work to address the drivers of AMR
-
develop international networks of antimicrobial resistance expertise
-
pursue strategic research themes to rapidly advance solutions to the most urgent issues
Working with our partners and the public, we will lead the development of novel solutions to this crisis and aim for implementation on a global scale.
In 2024, GSK pledged £45m in funding to back our mission to help tackle AMR around the world. This will be delivered through six Grand Challenges, harnessing some of the best scientific expertise and the latest technologies, including advanced AI, to find new ways to slow the progress of antimicrobial resistance (AMR).
The six Grand Challenges are:
-
Supercharging the discovery of new antibiotics for Gram-negative bacterial infections
-
Accelerating the discovery of new drugs to combat fungal infections
-
Improving understanding of how our immune systems respond to drug-resistant bacteria, starting with Staphylococcus aureus, to stimulate vaccines research
-
Using disease surveillance and environmental data to create AI models that predict how drug-resistant pathogens emerge and spread
-
Running an innovative clinical trial to improve how and when antibiotics are prescribed
-
Using international research data and insights to inform policy and public engagement, embed preventative interventions, accelerate continued R&D, and amplify societal and government action to get ahead of AMR ​​​
LifeArc is contributing a £25 million pledge to the Fleming Initiative and will harness their expertise in drug discovery, intellectual property management and technology transfer in this fight to address AMR. ​
Cepheid's significant pledge to the Fleming Initiative will be used for collaborative scientific and clinical research, with a focus on strengthening and expanding the use of in vitro diagnostics to support antimicrobial stewardship programs to enable responsible antibiotic use and control the rise of resistant infections. The collaboration will focus initially on the most critical areas of AMR:
-
Encourage active screening for carbapenemase-producing Enterobacteriaceae (CPE) for earlier detection of critical infections and colonization
-
Implementation of community-based acute respiratory infection (ARI) testing and care pathways to provide decentralized diagnostic and treatment pathways
-
Accelerate a precision medicine approach for sepsis to identify and treat patients with a particular sepsis response state ​
Optum will be the primary data and analytics partner for the Fleming Initiative, in order to help reduce the consequences of AMR infection and help people live healthier lives.
Innovative and creative collaborations
AI-powered technologies could be transformative in the AMR crisis, from enabling clinicians to make rapid diagnosis at point of need and helping discover new drugs that can tackle emerging resistant infections, to predicting the spread of resistant bacteria.
​
We have co-authored a report with Google DeepMind, with a consensus that AI systems will be far from delivering on this potential without investment in the necessary infrastructure, including data and robust evaluations; computing power; and in particular, training for those working in this critical area.
To enable the interdisciplinary capability needed to realise the potential of AI in tackling antimicrobial resistance, we have launched a new Google DeepMind Academic Fellowship.
Dr Nicholas Moser is appointed as the new Google DeepMind's Academic Fellow, and his fellowship will be co-hosted by the Department of Computing and Fleming Initiative.
The Fleming Initiative and Johns Hopkins University are forming a strategic partnership that will see Johns Hopkins serve as the Fleming Initiative’s Centre for the United States. Building on Johns Hopkins’ longstanding leadership in infectious diseases, the collaboration reflects a shared commitment to interdisciplinary approaches to tackling antimicrobial resistance (AMR). The partnership is aligned around advancing clinical trials, accelerating AMR technologies, and creating future opportunities to co-convene stakeholders to drive innovation and global impact. ​
​
Working with our partners and the public, we will lead the development of novel solutions to this crisis and aim for implementation on a global scale.
Partner with us
We warmly welcome opportunities to discuss how partnership and support might be realised.
Discover how you can help make the Fleming Initiative's vision a reality.